Connect with us

Technology

Piezo Therapeutics Announces Formation of Scientific Advisory Board with Industry Veterans and Academic Luminaries

Published

on

World-renowned experts across infectious diseases, vaccines, and dermatology to advise Piezo on advancing its energy-based delivery platform and internal programs to the clinic

ATLANTA, April 21, 2025 /PRNewswire-PRWeb/ — Piezo Therapeutics, a biotechnology company pioneering energy-driven genetic medicines, announced today the formation of its Scientific Advisory Board (“SAB”) with leaders in infectious diseases, vaccines, and skin biology. The inaugural SAB will work closely with Piezo’s leadership team to provide technical insights and strategic guidance as Piezo advances its energy-based delivery platform (Piezopen) for its wholly owned programs and with pharma/biotech partners. Members of Piezo’s SAB bring decades of experience across RNA vaccines and therapeutics, DNA medicines, drug delivery, and dermatology.

“Our distinguished SAB will allow the company to continue its commitment to the highest-quality science focused on addressing unmet medical needs through energy-driven genetic medicines.” – Mark Prausnitz, PhD, Piezo co-founder and Regents’ Professor at Georgia Tech

“We are honored to welcome an illustrious group of industry veterans and academic leaders to our SAB as we advance Piezopen to the clinic,” said Gaurav Byagathvalli, CEO of Piezo. “Our SAB members have dedicated their careers to advancing novel medicines and deciphering human biology to prevent and cure life-threatening diseases. We look forward to drawing upon their deep expertise across multiple therapeutic areas as we advance our internal programs and ongoing collaborations towards first-in-human studies.”

Mark Prausnitz, PhD, Piezo co-founder and Regents’ Professor at Georgia Tech, added that “Piezo was founded on rigorous science and technology development at Georgia Tech. Our distinguished SAB will allow the company to continue its commitment to the highest-quality science focused on addressing unmet medical needs through energy-driven genetic medicines.”

The SAB includes (in alphabetical order):

Dr. Kate Broderick, PhD: Dr. Broderick has more than 20 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery field. Prior to joining Maravai in 2022 as the Chief Innovation Officer, Dr. Broderick held roles of increasing responsibility at Inovio Pharmaceuticals, most recently as Senior Vice President, R&D. Dr. Broderick has served as a principal investigator for a variety of grants and awards from government agencies and non-profits, including the National Institutes of Health. She received her PhD from the University of Glasgow in Scotland and completed her post-doctoral research at the University of California, San Diego.Dr. Elaine Fuchs, PhD: Dr. Fuchs is renowned for her research in skin biology, its stem cells and associated disorders, including cancers and inflammation. She is an Investigator of the Howard Hughes Medical Institute and has published >380 manuscripts. She received her PhD from Princeton in Biochemistry, her postdoctorate in Cell Biology at MIT, and has been on the faculty, first at University of Chicago and now Rockefeller University. Her awards include the National Medal of Science, L’Oreal-UNESCO Award, International Society for Stem Cell Research’s Innovation Award, the Gairdner International Award and the Franklin Medal. Dr. Fuchs holds membership in the National Academy of Sciences, National Academy of Medicine, American Philosophical Society, Pontifical Academy of Sciences, and the Royal Society. She is an inaugural member of the Academy of the American Association for Cancer Research, and now serves as its President.Dr. Norbert Pardi, PhD: Dr. Pardi holds a PhD in biochemistry and genetics from the University of Szeged, Hungary. He has been working at the University of Pennsylvania since 2011 and currently holds an Associate Professor position at the Department of Microbiology of the Perelman School of Medicine. He received training from Drs. Katalin Kariko and Drew Weissman at the University of Pennsylvania before he started his laboratory. His research interest is the development of mRNA-based therapeutics with particular focus on new-generation infectious disease vaccines. He explored the development of a novel vaccine platform using nucleoside-modified mRNA in lipid nanoparticles (LNPs) and used it to generate highly effective vaccines targeting various pathogens (influenza virus, coronaviruses, malaria and others). Dr. Pardi is a pioneer of the nucleoside-modified mRNA vaccine technology and published milestone papers in the field.Dr. Jeffrey Ulmer, PhD: Dr. Ulmer spent more than 30 years in vaccines R&D at Merck Research Laboratories, Chiron Corporation, Novartis and GlaxoSmithKline. His most recent leadership positions included Global Head, External R&D; Head, Preclinical R&D; and Program Head, Technical R&D. His scientific focus has been vaccine technology platforms, including DNA and mRNA vaccines, viral vectors and adjuvants. He received his Ph.D. in biochemistry from McGill University and a postdoctoral fellowship in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. He has published over 220 scientific articles, is an inventor on 11 patents, and is a Fellow of the International Society for Vaccines, where he serves as Vice-Chair of the Executive Board. He is currently President and CEO of TechImmune LLC, a biotechnology company based in Newport Beach, CA.

About Piezopen Platform

Our proprietary Piezopen platform enables localized yet highly efficient delivery of RNA and DNA without the need for lipid nanoparticles or viral vectors, with applications in infectious disease, cancer, chronic disease, and dermatology. In preclinical models, we have demonstrated robust induction of humoral and cellular responses to infectious disease and cancer vaccines with increased tolerability, dosing flexibility, and payload versatility. In human subjects, Piezopen was well accepted and shown to elicit superior tolerability compared to a hypodermic needle. Piezopen combines two innovations to surpass the limitations of formulations: piezoelectric pulses and microelectrodes for energy-based nucleic acid delivery. Piezopen improves the tolerability and efficacy of RNA/DNA medicines while slashing costs, simplifying manufacturing, and transforming scalability.

About Piezo Therapeutics

Piezo Therapeutics is a spinout from Georgia Tech focused on enabling next-gen nucleic acid vaccines and therapeutics via energy-based delivery. Integrating innovations in drug delivery and genetic medicine, Piezo is advancing its delivery platform and investigational therapeutics in collaboration with global pharma and biotech companies to prevent and treat debilitating diseases. The company raised its initial financing in 2023 backed by Good Ventures. For more information, please visit www.piezotx.com.

Media Contact

Gaurav Byagathvalli, Piezo Therapeutics, 1 4049973263, partnerships@piezotx.com, www.piezotx.com

View original content to download multimedia:https://www.prweb.com/releases/piezo-therapeutics-announces-formation-of-scientific-advisory-board-with-industry-veterans-and-academic-luminaries-302429880.html

SOURCE Piezo Therapeutics

Continue Reading

Technology

Cash or Card? New Upgraded Points Survey Reveals How Travelers Pay Abroad

Published

on

By

AUSTIN, Texas, Oct. 28, 2026 /PRNewswire/ — A new Upgraded Points survey of 1,500 recent international travelers, including 1,000 Americans, finds that travelers use a mix of cash and cards abroad, but exchange rates, fees, and declined transactions can complicate purchases.

“Spending money should be the easy part of a trip abroad,” said Ryan Smith, Director of News at Upgraded Points. “But exchange rates, fees, and payment options can complicate even the simplest purchase. We wanted to learn how travelers prepare, where their plans run into trouble, and what they do when convenience and the best exchange rate move in different directions.”

Study Methodology

Upgraded Points surveyed 1,500 adults who had traveled internationally within the past 12 months, including 1,000 U.S. adults and 500 adults from other countries. Respondents answered questions about payment methods, cash habits, credit card use, airport currency exchanges, and their confidence navigating exchange rates. The results were compared to show how Americans’ payment habits differ from those of other international travelers.

Payment Planning Often Starts Months Before a Trip

Nearly one-third (32%) begin planning how they’ll pay abroad three to six months before departure. U.S. travelers are more likely than non-U.S. travelers to start earlier, with 20% beginning more than six months ahead, compared with 12% of non-U.S. travelers.

Travelers’ Confidence in Exchange Rates Varies

Just 35% of respondents said they feel very confident understanding exchange rates abroad. Confidence also varied by age and gender:

44% of men feel very confident, compared with 26% of women.28% of Gen Z travelers feel very confident, compared with 40% of Gen X travelers and 37% of Baby Boomers.

Cash and Cards Remain Popular Abroad

Cash in the local currency and physical credit cards were nearly tied as the payment methods travelers most often use abroad. Mobile wallets were more popular among younger travelers:

71% use cash in the local currency.69% use a physical credit card.44% use a mobile wallet, including 56% of Gen Z travelers and 22% of travelers age 61 and older.35% use a physical debit card.

Most Travelers Carry Local Currency

More than 8 in 10 travelers (81%) carry cash in the destination’s currency, often for situations where cards may not be accepted:

64% use it at street vendors, markets, or small businesses.55% use it for tips and other customary cash payments.53% carry it for emergencies.

Travelers generally avoid carrying a large amount at once. About 44% exchange enough cash for several days, while 26% exchange enough for the full trip.

Familiar Card Brands Lead Among U.S. Travelers

Among U.S. respondents, Visa was the most commonly used card network, while Chase and Capital One were the most commonly used issuers:

Visa: 24%Chase: 21%Capital One: 19%American Express: 15%

Fees and Declined Cards Can Complicate Purchases

Among all respondents, travelers most often said their bank or card company contacted them about a purchase made abroad. Other issues increased the cost of a purchase or prevented it from going through:

38% were contacted by their bank or card company about a purchase.34% paid more than expected because of the exchange rate.29% were charged an unexpected foreign transaction fee.26% had a card declined.

Find the full study here.

About Upgraded Points LLC

Headquartered in Austin, Texas, Upgraded Points is a travel company that helps to demystify the complex world of travel and credit cards. Launched in 2016 by Alex Miller, Upgraded Points uses targeted research efforts and in-depth studies to help travelers maximize their travel, points, and experiences. Learn more at www.UpgradedPoints.com.

Media Contact:
Alex Miller, Founder
1-214-646-8866
425187@email4pr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cash-or-card-new-upgraded-points-survey-reveals-how-travelers-pay-abroad-302922010.html

SOURCE Upgraded Points

Continue Reading

Technology

ESI supplying solar array components to missile defense programs

Published

on

By

SIMI VALLEY, Calif., Oct. 28, 2026 /PRNewswire/ — ESI Motion Inc. is proud to announce that it is supplying the Solar Array Drive Electronics (SADE) to Lockheed Martin for its work on the Space Development Agency’s Proliferated Warfighter Space Architecture (PWSA) programs.

Under the agreement, ESI Motion’s SADE technology will support SDA as the PWSA is developed.

Defending our nation in space is more important than ever. The Space Development Agency’s PWSA programs provide the military with a network of satellites with secure communication, missile tracking and space-based support to make sure our troops have the latest and greatest technology.

The SADE consists of our Space-rated, flight heritage, SuperNova and Pulsar motor controllers. These motion controllers ensure all mission parameters are fulfilled, with high-reliable technology. 

ESI Motion Inc., U.S. Company, is a trusted supplier and partner, supporting mission operations for space, military and industrial customers around the world for over 20 years. Please visit our website; www.esimotion.com

Mitchell Haerterich, mhaerterich@esimotion.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/esi-supplying-solar-array-components-to-missile-defense-programs-302922454.html

SOURCE ESI Motion

Continue Reading

Technology

Envoy AI Launches “Boss of Machines” Program to Develop the Next Generation of Freight Leaders

Published

on

By

New AI Operations Lab will provide college students with hands-on experience in freight technology, operational transformation, and a $2,500 scholarship.

CHATTANOOGA, Tenn., Oct. 28, 2026 /PRNewswire-PRWeb/ — Envoy AI, the AI Native platform behind logistics autonomous agent system and execution layer Ellie, today announced the launch of Boss of Machines: AI Operations Lab, a new internship and scholarship program designed to prepare the next generation of logistics professionals for an industry increasingly shaped by artificial intelligence and digital labor.

The people starting their careers in freight now are going to spend a lot of their day managing agents. Somebody has to be the boss of those machines. We named the program after that job because it’s the one brokerages are going to be hiring for.

The program was introduced by Envoy AI CEO Robby Nathan during his fireside chat at FreightWaves’ F3: Future of Freight Festival on October 27.

“Freight has always been a people business, and that isn’t changing,” said Robby Nathan, Envoy AI CEO. “What is changing is how the work gets done. We want students to understand that shift firsthand. There’s a big difference between learning about AI in a classroom and seeing what it takes to put it to work in a real operation. Our goal is to give them that experience and help prepare them to become the leaders this industry will need.”

Launching in spring 2027, the three-month program will select two college juniors or seniors for an immersive experience working directly with Envoy AI’s product, engineering, and operations teams. Participants will gain firsthand exposure to how AI technology is developed, implemented, and used to solve real operational challenges across the freight industry.

Preparing Students for a Changing Industry

As freight companies adopt AI to automate routine work, improve productivity, and scale operations, the skills future logistics leaders need are evolving.

The Boss of Machines program bridges the gap between classroom education and the practical experience needed to lead technology-enabled operations.

Students will participate in four areas of learning:

Building AI for Operations: Understanding how AI agents are developed and applied to freight workflows.Deploying Digital Labor: Learning how new technology is integrated into existing systems, implemented with customers, and adopted by operational teams.Measuring Operational Performance: Exploring the role of analytics, productivity, and return on investment in evaluating technology initiatives.Leading Modern Freight Operations: Developing an understanding of how people and AI agents work together to manage and execute freight operations.

Investing in the Next Generation

The initiative reflects Envoy AI’s commitment to developing talent and giving students meaningful exposure to the technology and operational practices shaping the future of transportation.

“About 75% of the freight in our live accounts is already booked through Ellie, and that changes the job a new hire walks into,” said Nathan. “The people starting their careers in freight now are going to spend a lot of their day managing agents. That takes someone who can tell when a rate doesn’t make sense for the lane, and who’ll catch a carrier about to fall off before the shipper ever hears about it. Somebody has to be the boss of those machines. We named the program after that job because it’s the one brokerages are going to be hiring for.”

Throughout the program, students will work alongside experienced industry professionals, gaining exposure to product development, customer implementations, operational workflows, and the business decisions involved in deploying AI at scale.

Upon successful completion of the three-month program, each participant will receive a $2,500 scholarship to support their fall 2027 studies.

Applications and Program Timeline

The inaugural Boss of Machines: AI Operations Lab will welcome two students for the spring 2027 semester.

The program is open to college juniors and seniors interested in logistics, supply chain management, technology, engineering, business operations, and related fields.

Applicants will be asked to share their interests, relevant experience, and perspectives on how technology can improve freight operations.

Envoy AI will announce selected participants in January 2027, ahead of the spring program kickoff.

Additional program details and application information will be available through Envoy AI’s website.

About Envoy AI

Envoy AI develops AI-powered digital labor solutions for freight and logistics operations. Through its AI workforce, Ellie, the company helps logistics teams automate operational workflows, improve productivity, and execute freight processes across existing transportation systems. Envoy AI helps transportation organizations scale operations through practical AI applications.

Media Contact

Michelle McBride, Envoy AI, 1 972-821-2012, michelle@tryenvoy.ai, tryenvoy.ai

View original content:https://www.prweb.com/releases/envoy-ai-launches-boss-of-machines-program-to-develop-the-next-generation-of-freight-leaders-302922133.html

SOURCE Envoy AI

Continue Reading

Trending